U.S. FDA panel rejects Avastin for breast cancer
SILVER SPRING, Md., June 29
SILVER SPRING, Md., June 29 (Reuters) - U.S. health advisers voted on Wednesday to reject using Roche Holding's drug Avastin for breast cancer while the Swiss drugmaker conducts more studies.
Roche (ROG.VX) stands to lose nearly $1 billion in Avastin revenue after the U.S. Food and Drug Administration advisers upheld the agency's decision to revoke the medicine's use in breast cancer.
Wrapping up a rare two-day appeal hearing, the panel also reiterated its view that Avastin is not clinically beneficial, effective or safe for treating breast cancer. (Reporting by Anna Yukhananov and Alina Selyukh. Editing by Robert MacMillan)
- Exclusive: Secret contract tied NSA and security industry pioneer |
- Obama girls get dating advice from their watchful dad
- Accused Colorado theater gunman competent to stand trial, evaluators say
- Seattle students protest gay Catholic school teacher's resignation
- Analysis: Lost Brazil order raises threat to Boeing fighter jets